Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

After Another NICE No, Will It Be Third Time Lucky For J&J's Spravato?

The healthcare giant's nasal spray for hard-to-treat depression has been rejected for use on the UK's NHS for a second time because of uncertainty over cost, but comments on this consultation could result in a change of fortunes for the potential blockbuster.

Market Access Neurology

Roche Rides Partnership, Digital Wave To Widen China Oncology Drug Access

Amid rising cancer incidence in the Asia Pacific region, Roche tells Scrip in this exclusive interview that it is going "beyond the pill" to widen access to drugs in the increasingly important oncology market.

China Commercial

Vertex Secures Rapid Deal In England For CF Triple Therapy

After a long-standing row with payer NHS England, the rapid market access deal will help Vertex move into growth phase.

Companies Commercial

G1 Believes Boehringer Is Better Bet To Sell Trilaciclib

G1 Therapeutics had been talking about marketing its recently filed myelosuppression therapy for small cell lung cancer on its own. However a deal with Boehringer represents an alternative "capital efficient launch structure."

Cancer Deals

$90m IPO Sets Up Sweden's Calliditas For Phase III Readout

The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.

Companies Commercial

Novartis Targets Quick Launches For Zolgensma in Europe

The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.

Approvals Gene Therapy

FDA Approval Makes Deciphera’s Qinlock First Fourth-Line GIST Drug

Qinlock (ripretinib), approved as the US FDA rejected Blueprint Medicines’ Ayvakit (avapritinib) in the same indication, is priced on par with the rival drug cleared in January for a narrower GIST use.

Launches Approvals

AZ To Adopt Indication-Based Pricing For Farxiga In Heart Failure

AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.

Pricing Strategies Cardiovascular

Alexion Buys Out Portola, But Analysts Don’t See Value

The acquisition brings Alexion the bleeding reversal agent Andexxa, which execs called a synergistic addition to its portfolio – but analysts are struggling to see the match with Alexion’s chronic rare disease therapies.

Deals M & A
See All
UsernamePublicRestriction

Register